Lyme disease in Immune-Suppressed patients under investigation

NCT ID NCT07343089

Recruiting now Knowledge-focused Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

First seen Jan 25, 2026 · Last updated Jun 16, 2026 · Updated 29 times

Summary

This study looks at cases of severe Lyme disease (disseminated borreliosis) in patients who have received anti-CD20 therapy, a type of immune-suppressing treatment. Researchers want to describe the symptoms, severity, and progression of the infection in these patients. The study will include up to 100 people in France who had confirmed Lyme disease within 24 months of receiving anti-CD20 treatment between 2010 and 2025.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BORRELIA INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Laboratoire de Bactériologie - CHU de Strasbourg - France
RECRUITING

Strasbourg, 67091, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

BORRELIA INFECTIONS